Connect Biopharma announced the online publication of positive results from its global Phase 2 trial of rademikibart in patients with moderate-to-severe uncontrolled asthma in the American Journal of Respiratory and Critical Care Medicine. These data highlight rademikibart’s potential as a novel biologic treatment option for patients with asthma and Type 2 inflammation.
The trial demonstrated a rapid onset of action, with significant improvements in lung function observed at one week and sustained through 24 weeks of treatment. In patients with eosinophilic-driven asthma (≥300 eosinophils/µL), the mean difference from placebo in forced expiratory volume in one second (FEV1) was +420 mL.
Based on these results, the U.S. Food and Drug Administration previously agreed to advance rademikibart into Phase 3 trials for the maintenance treatment of asthma. This publication reinforces the clinical profile of rademikibart and supports its further development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.